Patent Document ID: 9980928
Application ID: 15489186
Patent Flag: 1

Claim One:
1. A method of increasing neuroplasticity in a subject in need thereof, said subject being affected by at least one disorder selected from the group consisting of depression and fragile X syndrome, said method comprising administering to said subject a compound having formula (I) wherein, R 1 and R 3 represent hydrogen atoms; R 2 is a group A-OR 8 , wherein R 8 is selected from the group consisting of H; glycosyl; acetyl; valproyl and lipoyl; A is a biradical selected from the group consisting of C 1 -C 6 alkylene and C 2 -C 6 alkenylene R 4 is selected from the group consisting of: H; a C 5 -C 7 cycloalkyl, optionally substituted by at least one group selected from the group consisting of halogen, —OH, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —CN, —NO 2 , —COOH, and —NH 2 ; a C 6 -C 10 aryl, optionally substituted by at least one group selected from the group consisting of halogen, —OH, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —CN, —NO 2 , —COOH, and —NH 2 ; and a 5- or 6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms, said heteroatoms being independently selected from the group consisting of N, O and S; said heteroaryl being optionally substituted by at least one group selected from the group consisting of halogen, —OH, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —CN, —NO 2 , —COOH, and —NH 2 ; wherein: a) R 5 is selected from the group consisting of H and an 8-, 9- or 10-membered bicyclic heteroaryl containing 1 or 2 heteroatoms, said heteroatoms being independently selected from the group consisting of N, O and S; said heteroaryl being optionally substituted by at least one group selected from the group consisting of halogen, —OH, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —CN, —NO 2 , —COOH, and —NH 2 ; R 6 is selected from the group consisting of H; C 1 -C 3 alkyl and C 1 -C 8 acyl; and R 7 is selected from the group consisting of H and C 1 -C 3 alkyl; or b) R 5 and R 6 taken together form a group selected from the group consisting of —O—CH 2 —CH 2 — and —CH(R 11 )—CH 2 —CH 2 —, wherein R 11 is a phenyl group optionally substituted by at least one substituent selected from the group consisting of halogen; —OH and —NH 2 ; and R 7 is H; or c) R 5 is H; and R 6 and R 7 taken together form a group —(CH 2 ) m —CO—; n is an integer selected from 0, 1 and 2; m is an integer selected from 2, 3 and 4; with the proviso that when R 4 and R 5 are both H, then R 6 and R 7 taken together form a group —(CH 2 ) m —CO—; or a pharmaceutically acceptable salt or stereoisomer thereof.